Argitalpenak (103) MARÍA GALINDO IZQUIERDO argitalpenak

2024

  1. Correction to: Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care (BMC Rheumatology, (2024), 8, 1, (31), 10.1186/s41927-024-00401-x)

    BMC Rheumatology

  2. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)

    Rheumatology International, Vol. 44, Núm. 11, pp. 2445-2455

  3. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?

    Rheumatology (Oxford, England), Vol. 63, Núm. 1, pp. 72-78

  4. Lack of awareness of systemic lupus erythematosus and its consequences in a cohort of moderate and severe patients in Spain: The LupusVoice study

    Lupus, Vol. 33, Núm. 7, pp. 663-674

  5. Lupus Nephritis: 10 questions to think about

    Nefrologia

  6. Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus

    Reumatologia Clinica, Vol. 20, Núm. 6, pp. 312-319

  7. Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care

    BMC Rheumatology, Vol. 8, Núm. 1

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Gender biases in Spanish rheumatology: Perception and facts

    Reumatologia Clinica, Vol. 19, Núm. 7, pp. 392-401

  3. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

    Rheumatology and Therapy, Vol. 10, Núm. 2, pp. 357-373

  4. Lupus nephropathy beyond immunosuppression: Searching for nephro and cardioprotection

    Frontiers in Nephrology

  5. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 61

  6. Searching for a prognostic index in lupus nephritis

    European journal of medical research, Vol. 28, Núm. 1, pp. 19

  7. mTOR inhibitors in a patient with lupus nephritis; why not?

    Nefrologia

  8. mTOR inhibitors in a patient with lupus nephritis; why not?

    Nefrologia

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224

  3. Importance of family planning in patients with immune-mediated inflammatory diseases: a multidisciplinary approach

    Reumatologia Clinica, Vol. 18, Núm. 4, pp. 200-206

  4. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 9, pp. 1337-1338

  5. Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines

    European Journal of Internal Medicine, Vol. 99, pp. 19-21